Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
B-cell and hematologic antigen antibodies bind surface markers of B cells, plasma cells and myeloid leukemia cells. Rituximab, ofatumumab and obinutuzumab target CD20, while tafasitamab and inebilizumab bind CD19 on B cells. Daratumumab and isatuximab bind CD38, and elotuzumab binds signaling lymphocytic activation molecule F7 (SLAMF7) on myeloma cells. Belantamab targets B-cell maturation antigen (BCMA), and brentuximab targets CD30 on Hodgkin and anaplastic lymphoma cells. Further antibodies cover CD22, CD33, CD37, CD123, B-cell activating factor (BAFF) and leukocyte adhesion molecules.
Indatuximab is a chimeric antibody of the VHH-Fc (huIgG1) type, expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target Syndecan-1/CD138. This antibody has a predicted molecular weight of 146.1 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control is recommended as the isotype control for Indatuximab.
Synonyms: IMGN-779 antibody
The Anti-CD33 Antibody (IMGN-779) is a humanized antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Siglec-3/CD33. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 144.6 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focusing on the biological role and therapeutic targeting of CD33 in various diseases.
Synonyms: CEN 000029; cM-T412
Priliximab (CEN 000029) is a humanized monoclonal antibody targeting CD4, a surface glycoprotein predominantly expressed on T cells. By binding to CD4, Priliximab induces a significant and sustained decrease in circulating CD4+ T cell populations. This antibody is primarily utilized in the investigation of immune response mechanisms in conditions such as rheumatoid arthritis (RA), providing valuable insights into therapeutic strategies aimed at modulating T cell activity.
Synonyms: GSK2857914
Belantamab (GSK2857916) is a humanized IgG1 monoclonal antibody targeting BCMA (B-cell maturation antigen), also known as TNFRSF17. This antibody is conjugated to the cytotoxic agent monomethyl auristatin F (MMAF) via a non-cleavable linker, forming the antibody-drug conjugate (ADC) Belantamab mafodotin. Upon binding to BCMA expressed on the surface of tumor cells, Belantamab mafodotin is internalized through receptor-mediated endocytosis. Inside the cell, the conjugate releases MMAF, which inhibits tubulin polymerization, leading to cell cycle arrest and subsequent induction of apoptosis in the tumor cells. This mechanism positions Belantamab mafodotin as a potent therapeutic agent for the investigation of multiple myeloma, particularly in cases of relapsed or refractory disease.
Erzotabart is a monoclonal antibody of the IgG1-kappa subtype that targets CD38 (also known as ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, or cADPR hydrolase 1) in Homo sapiens. This antibody exhibits antineoplastic activity, making it a valuable tool for research in cancer therapy.
Taplitumomab is a monoclonal antibody targeting CD19, a protein primarily expressed on the surface of B cells. This specificity makes Taplitumomab a valuable tool in cancer research, particularly for studying B-cell malignancies. The conjugated form, Taplitumomab paptox, incorporates a toxin for targeted cytotoxic activity, enhancing its utility in investigating therapeutic approaches for cancer treatment.
Synonyms: Hu1D10
Apolizumab (Hu1D10) is a humanized monoclonal antibody targeting the Human Leukocyte Antigen-DR beta-chain (HLA-DR beta-chain). This antibody has demonstrated the capability to mediate apoptosis in chronic lymphocytic leukemia (CLL) cells in vitro, suggesting its potential utility in research focused on the mechanisms of CLL pathology and therapeutic interventions.
Synonyms: XmAb5871
Obexelimab (XmAb5871) is a humanized monoclonal antibody targeting CD19, a protein expressed on the surface of B cells. This antibody functions by inhibiting the B cell receptor (BCR)-mediated calcium influx and enhancing the phosphorylation of Fcγ receptor IIb (FcγRIIb). These actions collectively diminish B cell activation and functionality, ultimately inducing B cell apoptosis. Obexelimab is primarily utilized in research studies focusing on autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.
Azintuxizumab is a human IgG4κ monoclonal antibody targeting SLAMF7. It is designed for use in the development of antibody-drug conjugates, specifically Azintuxizumab vedotin. This antibody is engineered for precise binding to the SLAMF7 antigen, making it a critical component in targeted cancer therapy research.
Synonyms: AFM13
Acimtamig (AFM13) is a bispecific innate cell engager targeting CD30 and CD16A. This therapeutic agent facilitates the selective cross-linking between natural killer (NK) cells, through CD16A engagement, and CD30-expressing tumor cells. The dual binding capability of Acimtamig enhances the cytotoxic potential of NK cells against targeted tumor cells, making it an invaluable tool for investigating the pathophysiology and potential treatments of peripheral T-cell lymphoma (PTCL).
Lumrotatug is a human IgG1 κ monoclonal antibody targeting CD38. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.
Synonyms: 3BNC117-LS; GS-5423
Teropavimab (3BNC117-LS) is a monoclonal antibody specifically designed for the study of HIV infection. This antibody targets the CD4-binding site of the HIV-1 envelope glycoprotein, making it a valuable tool for researchers investigating viral entry mechanisms and immune evasion strategies. Its application in HIV research provides critical insights into the development of potential therapeutic interventions.
Synonyms: MCDS0593A
Iladatuzumab (MCDS0593A) is a humanized IgG1 monoclonal antibody targeting CD79B, a molecule predominantly expressed on B cells. This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), such as Iladatuzumab vedotin (DCDS0780A). Iladatuzumab vedotin is specifically designed for research applications in B-cell non-Hodgkin lymphoma (B-NHL), offering potential insights into therapeutic strategies for this malignancy.
Synonyms: MDX-060
Iratumumab (MDX-060) is a humanized IgG1κ monoclonal antibody specifically targeting CD30, a cell surface antigen. This antibody effectively inhibits the proliferation of tumor cells expressing CD30. It is primarily utilized in scientific studies focused on Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), providing a valuable tool for research into the pathophysiology and potential therapeutic approaches for these malignancies.
Synonyms: Anti-Human CD33 Recombinant Antibody
Vadastuximab is a humanized monoclonal antibody designed to specifically target CD33, a transmembrane receptor expressed on cells predominantly in myeloid lineages. This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), notably Vadastuximab talirine. This application highlights its potential in targeted cancer therapy, particularly for the treatment of acute myeloid leukemia (AML) where CD33 is commonly overexpressed.
Synonyms: GEN-3009
Ivicentamab (GEN-3009) is a bispecific monoclonal antibody of the IgG1κ subtype designed to target distinct epitopes on the CD37 antigen. This antibody is specifically engineered for the study of various cancer types, providing a valuable tool for detailed cancer research investigations.
Polatuzumab is a monoclonal antibody specifically designed to bind to CD79b, a protein expressed on the surface of B cells. This antibody serves as a foundational component for the creation of the antibody-drug conjugate (ADC) Polatuzumab Vedotin, which exhibits potent anti-tumor properties. This targeted approach allows for the direct delivery of cytotoxic agents to malignant cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. Polatuzumab and its derivatives are pivotal in advancing research and treatment options in oncology, particularly in the study and management of hematological malignancies.
Synonyms: hBU 12
Denintuzumab (hBU 12) is a recombinant humanized monoclonal antibody targeting CD19. This antibody serves as a critical component in the development of antibody-drug conjugates (ADCs), specifically in the synthesis of Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin is primarily utilized in research focused on acute lymphoblastic leukemia, providing a targeted therapeutic approach by delivering cytotoxic drugs directly to CD19-expressing cells. This specificity makes Denintuzumab an invaluable tool in the advancement of leukemia therapeutics.
Synonyms: Anti-Human selectin P Recombinant Antibody
Inclacumab is a recombinant human monoclonal IgG4 antibody that exhibits high selectivity for P-selectin, with a dissociation constant (Kd) of 9.9 nM. This antibody effectively inhibits the interaction between P-selectin and its ligand, P-selectin glycoprotein ligand 1 (PSGL-1), with a half-maximal inhibitory concentration (IC50) of 1.9 μg/mL. It is particularly effective in blocking cell adhesion mediated by P-selectin, making it a valuable tool for research into inflammatory and cardiovascular diseases where P-selectin plays a key role.
Mozistobart is a humanized IgG1κ monoclonal antibody that specifically targets CD22. For experimental controls, the recommended isotype control is Human IgG1 kappa.
The Anti-PTPRC/CD45 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45. This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for research focusing on immune cell signaling and function, as CD45 is pivotal in activating and regulating T and B cell receptor signaling pathways.
Apamistamab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting PTPRC/CD45. This antibody is composed of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, exhibiting a predicted molecular weight of 146.52 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.
Synonyms: TRU-016
Otlertuzumab (TRU-016) is a humanized monoclonal antibody targeting CD37, designed for use in cancer research. This antibody selectively binds to the CD37 antigen, a protein predominantly expressed on the surface of B cells, making it a valuable tool for studying B-cell malignancies. Otlertuzumab is utilized in various experimental settings to investigate its potential as a therapeutic agent in treating hematological cancers.
